Drug intelligence / Profile preview

carmustine + temozolomide

Development stage: Unknown
Lead developer: North American Brain Tumor Consortium
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination chemotherapy regimen consisting of carmustine (BCNU) and temozolomide. Both are alkylating agents that work by damaging DNA in cancer cells, preventing them from dividing and growing. The combination has been studied primarily for treating brain tumors, particularly glioblastoma and other refractory cancers. In clinical trials, the recommended dose and schedule was BCNU 150 mg/m² intravenously followed in 2 hours by temozolomide 550 mg/m² orally, repeated every 6 weeks.

Brand names: BiCNUTemodarTemodal
Other names: 1,3-bis(2-chloroethyl)-1-nitrosourea + temozolomidebis-chloroethyl-nitroso-urea + temozolomide

Targets

DNA

Beyond the preview

Go deeper on carmustine + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carmustine + temozolomide.

Explore the full profile